1-Butyl-2-Amino-3-(benzimidazol-2-yl)pyrrolo<2,3-b>quinoxaline | 120340-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-Butyl-2-Amino-3-(benzimidazol-2-yl)pyrrolo<2,3-b>quinoxaline
• 英文别名: 3-(1H-benzimidazol-2-yl)-1-butyl-1H-pyrrolo[2,3-b]quinoxalin-2-amine；3-(1H-benzimidazol-2-yl)-1-butylpyrrolo[3,2-b]quinoxalin-2-amine
• CAS: 120340-84-3
• 化学式: C₂₁H₂₀N₆
• 分子量: 356.43
• InChiKey: TWVBEWVBFFGPTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  85.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,3-二氯喹喔啉 在 potassium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 1-Butyl-2-Amino-3-(benzimidazol-2-yl)pyrrolo<2,3-b>quinoxaline
  参考文献：
  名称：

  （HET）取代乙腈的芳基化。1. 2-氨基-3-（苯并咪唑-2-基）吡咯并[2,3，b]-喹喔啉的合成

  摘要：

  DOI：

  10.1007/bf00479351

文献信息

• Substituted benzoxazepine for cancer therapy
  申请人：University of Cape Town

  公开号：US10220033B2

  公开（公告）日：2019-03-05

  Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.

  本发明的实施方案包括一种通过向有需要的患者施用治疗有效量的取代苯并氧氮杂卓来抑制核仁素β1活性的化合物和方法。式II化合物，9-[(1-甲基哌啶-3-基)甲氧基]-4-[(6-甲基吡啶-2-基)甲基]-7-(5-甲基噻吩-2-基)-3,5-二氢-2H-1,4-苯并氧氮杂卓或其盐之一，可抑制蛋白质和转录因子，如NFAT和P65/NFKB导入细胞核，从而具有抗癌作用，使该化合物可用于癌症治疗。
• KOZYNCHENKO, A. P.;VOLOVENKO, YU. M.;PROMONENKOV, V. K.;TUROV, A. V.;BABI+, XIMIYA GETEROTSIKL. SOED.,(1988) N 8, S. 1119-1123
  作者：KOZYNCHENKO, A. P.、VOLOVENKO, YU. M.、PROMONENKOV, V. K.、TUROV, A. V.、BABI+

  DOI：——

  日期：——
• SMALL MOLECULE INHIBITORS FOR CANCER THERAPY
  申请人：University of Cape Town

  公开号：EP3193863B1

  公开（公告）日：2022-07-13
• SUBSTITUTED BENZOXAZEPINE FOR CANCER THERAPY
  申请人：University of Cape Town

  公开号：US20180221368A1

  公开（公告）日：2018-08-09

  Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.
• COMPOSITIONS AND METHODS FOR INHIBITION OF NUCLEAR-PENETRATING ANTIBODIES
  申请人：Yale University

  公开号：US20210137960A1

  公开（公告）日：2021-05-13

  Compositions and methods of treating autoimmune diseases by administering a subject in need thereof an effective amount of an inhibitor of the importin pathway are also provided. Typically, the autoimmune disease has one or more symptoms or pathologies dependent on or otherwise caused by nuclear penetrating antibodies, for example, nuclear penetrating autoantibodies. In specific embodiments, the autoimmune disease is scleroderma or a form of lupus, for example systemic lupus erythematosus. In preferred embodiments, the inhibitor of the importin pathway is a macrocyclic lactone such as an avermectin or a milbemycin. Compositions, formulations, and dosage forms including an effective amount of the macrocyclic lactones to reduce nuclear localization of a nuclear penetrating antibody are also provided. The compositions can be employed in the disclosed methods. Exemplary dosages ranges and dosage regimens are also provided.